Dr.NIKITA DASH
AIM:To compare efficacy b/w bepotastine besilate1.5% v/s OlopatadineHCl 0.2% in symptomatic relief & patient perceived comfort in VKC.
METHODS: Prospective study of 68 VKC patients done over 8months period (Sept’16-Apr’17). 2 groups allocated:Group-1 received Olopatadine HCl in RE & placebo in LE & Group-2 received Bepotastine besilate in RE & placebo in LE with twice daily dosage & preservative-free artificial tears as placebo. Before t/t findings noted & after initiation of t/t,patients evaluated on days 4, 8 and 15 for improvement in signs & symptoms.
RESULTS: 4th Day: Grp2(67.6%) showed greater relief in symptoms than Grp1(52.9%).8th Day: all signs & symptoms subsided in Grp2 but itching & FB sensation not relieved in 14.7 % in Grp1. By day 15, all signs & symptoms had subsided in both groups. Placebo treated eyes showed no improvement.
CONCLUSION:Bepotastine besilate1.5 % is superior to oloptadine HCl 0.2% in the relief of symptoms & patient perceived comfort in VKC.
Leave a Comment